Opko Health Inc. (NYSE:OPK) CEO Phillip Md Et Al Frost acquired 1,800 shares of the firm’s stock in a transaction that occurred on Tuesday, September 20th. The shares were bought at an average cost of $10.36 per share, for a total transaction of $18,648.00. Following the purchase, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at $31,794,332.36. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Monday, September 19th, Phillip Md Et Al Frost acquired 1,800 shares of Opko Health stock. The shares were bought at an average cost of $10.18 per share, for a total transaction of $18,324.00.
  • On Tuesday, September 13th, Phillip Md Et Al Frost acquired 10,000 shares of Opko Health stock. The shares were bought at an average cost of $9.95 per share, for a total transaction of $99,500.00.
  • On Monday, September 12th, Phillip Md Et Al Frost acquired 10,000 shares of Opko Health stock. The shares were bought at an average cost of $9.79 per share, for a total transaction of $97,900.00.
  • On Friday, September 9th, Phillip Md Et Al Frost acquired 3,600 shares of Opko Health stock. The shares were bought at an average cost of $9.87 per share, for a total transaction of $35,532.00.
  • On Friday, September 2nd, Phillip Md Et Al Frost acquired 10,000 shares of Opko Health stock. The shares were bought at an average cost of $9.28 per share, for a total transaction of $92,800.00.
  • On Thursday, August 25th, Phillip Md Et Al Frost acquired 48,400 shares of Opko Health stock. The shares were bought at an average cost of $9.06 per share, for a total transaction of $438,504.00.
  • On Wednesday, August 24th, Phillip Md Et Al Frost purchased 15,000 shares of Opko Health stock. The stock was acquired at an average cost of $9.24 per share, for a total transaction of $138,600.00.
  • On Tuesday, August 23rd, Phillip Md Et Al Frost purchased 29,000 shares of Opko Health stock. The stock was acquired at an average cost of $9.53 per share, for a total transaction of $276,370.00.
  • On Monday, August 22nd, Phillip Md Et Al Frost purchased 11,800 shares of Opko Health stock. The stock was acquired at an average cost of $9.76 per share, for a total transaction of $115,168.00.
  • On Friday, August 19th, Phillip Md Et Al Frost purchased 15,000 shares of Opko Health stock. The stock was acquired at an average cost of $9.82 per share, for a total transaction of $147,300.00.

Shares of Opko Health Inc. (NYSE:OPK) opened at 10.68 on Thursday. Opko Health Inc. has a one year low of $7.12 and a one year high of $11.85. The stock has a market capitalization of $5.88 billion and a P/E ratio of 44.69. The company’s 50 day moving average price is $9.82 and its 200 day moving average price is $10.09.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/opko-health-inc-opk-ceo-buys-18648-00-in-stock.html

Opko Health (NYSE:OPK) last announced its earnings results on Monday, August 8th. The company reported $0.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.05. The company had revenue of $357.10 million for the quarter, compared to analyst estimates of $324.11 million. The firm’s revenue for the quarter was up 742.2% on a year-over-year basis. During the same period last year, the firm earned ($0.09) earnings per share. On average, equities analysts expect that Opko Health Inc. will post ($0.05) earnings per share for the current year.

A number of brokerages have issued reports on OPK. Standpoint Research began coverage on Opko Health in a research note on Friday, June 3rd. They issued a “buy” rating and a $16.00 price target on the stock. Oppenheimer Holdings Inc. reissued a “hold” rating on shares of Opko Health in a research note on Tuesday, May 31st. JPMorgan Chase & Co. set a $14.00 price target on Opko Health and gave the stock a “buy” rating in a research note on Tuesday, August 9th. Jefferies Group reissued a “hold” rating on shares of Opko Health in a research note on Wednesday, August 17th. Finally, Zacks Investment Research raised Opko Health from a “sell” rating to a “hold” rating in a research note on Tuesday, July 12th. Five research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $13.20.

Several large investors have recently made changes to their positions in OPK. Geode Capital Management LLC raised its stake in shares of Opko Health by 6.6% in the first quarter. Geode Capital Management LLC now owns 1,923,455 shares of the company’s stock worth $19,984,000 after buying an additional 118,512 shares during the period. Fairfield Bush & CO. raised its stake in shares of Opko Health by 51.2% in the first quarter. Fairfield Bush & CO. now owns 104,613 shares of the company’s stock worth $1,087,000 after buying an additional 35,425 shares during the period. Acrospire Investment Management LLC bought a new stake in shares of Opko Health during the first quarter worth about $218,000. Provident Investment Management Inc. bought a new stake in shares of Opko Health during the first quarter worth about $414,000. Finally, BlackRock Group LTD raised its stake in shares of Opko Health by 19.1% in the first quarter. BlackRock Group LTD now owns 251,817 shares of the company’s stock worth $2,616,000 after buying an additional 40,321 shares during the period.

Opko Health Company Profile

OPKO Health, Inc (OPKO) is a healthcare company. The Company operates through two segments: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations.

5 Day Chart for NYSE:OPK

Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.